Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors.
Javier García-SánchezMayra Alejandra Mafla-EspañaMaría Dolores TorregrosaOmar CauliPublished in: Biomedicines (2022)
Hormonal concentrations before AROi treatment constitute possible biomarkers to predict the progression of frailty syndrome.